T-CELL LYMPHOMA

This study tests adding the drug mogamulizumab to standard chemotherapy for people with aggressive T-cell lymphoma, a type of blood cancer. About 22 adults with newly diagnosed or returning lymphoma will receive the combination treatment. The goal is to see if more patients achie…

This study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…

This early-phase trial tests a new form of the drug fenretinide (ST-001) in people with T-cell non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard therapy. The main goals are to find the safest dose and to watch for side effects. About 46 adults with …

This study tests enasidenib, a drug that targets cancer cells with a specific IDH2 mutation, in people with angioimmunoblastic T-cell lymphoma (AITL). The drug is given alone or with rituximab. The goal is to see if it safely shrinks tumors. About 25 adults whose lymphoma has ret…

This study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent the lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body. A…

This study is for people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not improved with standard treatments. It tests a new drug called BI-1808, given alone or with another drug (pembrolizumab), to see if it is safe and to find the best dose…

This study tests a new treatment using specially engineered immune cells (CAR-T cells) that target a protein called CD5 on cancer cells. It is for people aged 3 to 70 with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to standard treat…

This early-phase trial tests a new treatment called CD4CAR for people with T-cell leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The m…

This study is creating a large database of information and tumor samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and find ways to improve patient outcomes. Participants provide medical history and a tumor sample, but …

This study looks at how the body handles venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. The…